Podcast
The Fellow on Call: The Heme/Onc Podcast
Hosted by Rouleaux University Medical Center · EN
We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.
30episodes
Episodes
Newest firstAll episodes
Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory
3d agoSummary readyThis week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on the topics discussed here today!Content: - What are options after steroids?- How to counsel patients on options? - Is there a correct way to sequence available options? ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management
1w agoSummary readyThis week, we go back to Classical Hematology! We previously discussed the initial workup and management of ITP in Episode 009, but now it’s time to dig deeper. What do we do once we make the diagnosis? How do we approach management when we have a new diagnosis? Content: - Refresher on diagnosis of ITP- Response criteria - What warrants a hospital admission vs. outpatient management? - What is our approach to initial inpatient management? - When is it safe to discharge a patient from the hospital?** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 154: Ask The Program Directors-The Do’s and Don'ts of Applying to Hematology Fellowship (Career Development Series)
May 20Summary readyThis week, we are so excited to share the second episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!With fellowship application season around the corner, we thought that this was the perfect time to understand what program directors are looking for in their applicants. This time, we welcome Dr. Alice Ma, Hematology/Oncology Fellowship Director at UNC, and Dr. Gerald Hsu, Hematology/Oncology Fellowship Director at UCSF. Along with our guest hosts, Nick and Claire, we ask the tough questions that all of wish we could ask but never could. This is an episode you do not want to miss! ** This episode is created in partnership with The American Society of Hematology (https://www.hematology.org/), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoiesis (https://www.hematology.org/education/trainees/fellows/hematopoiesis) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing
Apr 22Summary readyTherapy, Maintenance, and Relapsed/Refractory SequencingThis week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting.In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients.If you have not already done so, be sure to check out Part 1 of this discussion!Content:- What are the practical implications of MRD-testing in myeloma treatment?- How do we think about maintenance therapy in the present day? - What therapies are on the horizon? - How do we approach management of younger patients with relapsed/refractory disease?- How do we approach bridging therapy? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows. As a special bonus, one of our guests, Dr. Mohyuddin, is an expert on Primum ready for your questions!** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 152: Myeloma Capstone, Pt 1 - Smoldering Myeloma & Frontline Treatment in the Elderly
Apr 15Summary readyThis week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part one, we tackle two highly practical topics: the AQUILA trial and its real-world implications for smoldering myeloma management, and how to approach frontline therapy in the older myeloma patient.In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients. Stay tuned for part 2 of this discussion next week! Content:- How do our experts approach the management of smoldering multiple myeloma in light of the AQUILA study - What is our experts' approach to older patients with newly diagnosed multiple myeloma ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026)
Apr 8Summary readyIn this week’s episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don’t want to miss.If you haven’t done so already, be sure to check out our CAR T episode.Content:- What are bispecific T-cell engagers? - How are they different than CAR T? - A discussion of the pivotal MajesTEC-3 trial (NEJM 2025) - What are key side effects?- How to sequence CAR T vs. bispecific T-cell engagers? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 150: Myeloma Series, Pt. 10 - Role of CAR T for relapsed/refractory multiple myeloma (2026)
Apr 1Summary readyIn this week’s episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don’t want to miss. Content:- What are treatment options for patients with relapsed/refractory multiple myeloma (R/R MM)? - What is CAR T therapy? And what role does it play in R/R MM?- What are the available options for CAR T for R/R MM?- What are the toxicity profiles of available agents? - How to choose between the options?** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 149: Myeloma Series, Pt. 9 - Maintenance for Multiple Myeloma (2026)
Mar 18Summary readyThis week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who are able to undergo a transplant, we have consolidated their disease with a transplant; and now, we want to maintain that response using a lower dose of therapy, all while trying to minimize toxicity and maximize the patient’s quality of life. We discuss this in detail in this week’s episode!Content:- Why is lenolidomide (revlimid) our current standard of care?- What data do we have to add anti CD38 antibodies?- How is MRD being considered in this space? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 148: Myeloma Series, Pt. 8- Transplant in Multiple Myeloma (2026)
Mar 12Summary readyThroughout this series, we have discussed that for eligible patients, the current standard of care is to take patients for autologous stem cell transplant as consolidation for their multiple myeloma. In this reboot episode, we sit down with two incredible hematologists who specialize in transplant to discuss the real-life decision-making that goes into evaluating each patient. We are so excited to welcome two special guests this week, Dr. Shonali Midha and Dr. Amar Kelkar, joining us from the Dana-Farber Cancer Institute in Boston!Content:- What goes into determining if a patient is transplant eligible?- What counseling is provided to patients? - Approach to melphalan dosing- How does apheresis work? - What agents are used to help mobilize stem cells? - How many stem cells do we need to collect?- Does how much therapy one has received affect their collection? - Is there still a role for transplant in today's world?- Is there a role for an "MRD-adapted" approach to treatment?- Is there a role for a second transplant in patients who have relapsed?- Is there a role for allogeneic stem cell transplants in myeloma?A huge THANK YOU to our guests, Dr. Shonali Midha and Dr. Amar Kelkar, both of the Dana-Farber Cancer Institute!** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary
Episode 147: Myeloma Series, Pt. 7 - Transplant Consolidation for Multiple Myeloma (2026)
Mar 11Summary readyThis week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and the MIDAS Trial.Content:- What is the role of autologous stem cell transplant in the management of multiple myeloma? - How did we get to our current standards of care?- How is minimal residual disease (MRD) fitting into our treatment paradigm?** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube
Summary